Switch theme
Sign up to access all valuation multiples
GlaxoSmithKline Pharmaceuticals Ltd is an India-based subsidiary of GlaxoSmithKline plc. GSK India develops and manufactures medicines, vaccines, and consumer products. Its medicines portfolio includes prescription drugs for conditions that include asthma, infectious diseases, mental health, and digestion, as well as nonprescription nutrition and cosmetic products. Its vaccines product line includes treatments for conditions such as influenza, HPV, hepatitis, and measles. Its consumer healthcare products include Horlicks-brand packaged food and beverage powders among other retail products. The company derives majority of its revenue from India.
1924
3.2K+
LTM Revenue $438M
LTM EBITDA $133M
$5.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
GSK India has a last 12-month revenue of $438M and a last 12-month EBITDA of $133M.
In the most recent fiscal year, GSK India achieved revenue of $400M and an EBITDA of $103M.
GSK India expects next 12-month revenue of XXX and NTM EBITDA of XXX
See GSK India valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $375M | $400M | XXX | XXX | XXX |
| Gross Profit | $211M | $217M | XXX | XXX | XXX |
| Gross Margin | 56% | 54% | XXX | XXX | XXX |
| EBITDA | $105M | $103M | XXX | XXX | XXX |
| EBITDA Margin | 28% | 26% | XXX | XXX | XXX |
| Net Profit | $197M | $70.9M | XXX | XXX | XXX |
| Net Margin | 53% | 18% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, GSK India's stock price is INR 2747 (or $32).
GSK India has current market cap of INR 465B (or $5.4B), and EV of INR 444B (or $5.2B).
See GSK India trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.2B | $5.4B | XXX | XXX | XXX | XXX | $0.62 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, GSK India has market cap of $5.4B and EV of $5.2B.
GSK India's trades at 11.8x LTM EV/Revenue multiple, and 38.8x LTM EBITDA.
Analysts estimate GSK India's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for GSK India and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $5.2B | XXX | XXX | XXX |
| EV/Revenue | 12.1x | XXX | XXX | XXX |
| EV/EBITDA | 41.2x | XXX | XXX | XXX |
| P/E | 57.1x | XXX | XXX | XXX |
| P/E/Growth | 3.5x | XXX | XXX | XXX |
| EV/FCF | 55.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGSK India's NTM/LTM revenue growth is 10%
GSK India's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $43K for the same period.
Over next 12 months, GSK India's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate GSK India's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for GSK India and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -2% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 39% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $43K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 34% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GSK India acquired XXX companies to date.
Last acquisition by GSK India was XXXXXXXX, XXXXX XXXXX XXXXXX . GSK India acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was GSK India founded? | GSK India was founded in 1924. |
| Where is GSK India headquartered? | GSK India is headquartered in India. |
| How many employees does GSK India have? | As of today, GSK India has 3.2K+ employees. |
| Is GSK India publicy listed? | Yes, GSK India is a public company listed on BOM. |
| What is the stock symbol of GSK India? | GSK India trades under 500660 ticker. |
| When did GSK India go public? | GSK India went public in 1991. |
| Who are competitors of GSK India? | Similar companies to GSK India include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of GSK India? | GSK India's current market cap is $5.4B |
| What is the current revenue of GSK India? | GSK India's last 12-month revenue is $438M. |
| What is the current EBITDA of GSK India? | GSK India's last 12-month EBITDA is $133M. |
| What is the current EV/Revenue multiple of GSK India? | Current revenue multiple of GSK India is 11.8x. |
| What is the current EV/EBITDA multiple of GSK India? | Current EBITDA multiple of GSK India is 38.8x. |
| What is the current revenue growth of GSK India? | GSK India revenue growth between 2023 and 2024 was 7%. |
| Is GSK India profitable? | Yes, GSK India is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
